Compare AEHL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEHL | MOLN |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 137.2M |
| IPO Year | 2009 | 2021 |
| Metric | AEHL | MOLN |
|---|---|---|
| Price | $10.25 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | ★ 1.5M | 1.8K |
| Earning Date | 07-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $3.09 |
| 52 Week High | $30.60 | $5.36 |
| Indicator | AEHL | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 31.61 |
| Support Level | $0.83 | N/A |
| Resistance Level | $16.79 | $4.21 |
| Average True Range (ATR) | 1.95 | 0.11 |
| MACD | 0.25 | -0.04 |
| Stochastic Oscillator | 31.56 | 1.23 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.